ObjectiveTo investigate the clinical efficacy of indacaterol combined with tiotropium bromide in the treatment of patients with chronic obstructive pulmonary disease. Methods80 patients with moderate and severe chronic obstructive pulmonary disease (COPD) in stable period were randomly divided into four groups, 120 cases in each group. The blank control group did not give any anticholinergic drugs and beta 2-receptor agonist inhalation therapy. The tiotropium bromide group received tiotropium bromide inhalation therapy. The indacaterol group received indacaterol inhalation therapy. The combined treatment group given indacaterol plus tiotropium bromide inhalation therapy. The four groups were treated for 2 months. The scores of lung function and BODE index were compared between the four groups before and after treatment. Acute exacerbation and adverse reactions were compared during the period of treatment. ResultsAfter the course of treatment, the FEV1% and FEV1/FVC in the Indatero group, the tiotropium bromide group and the combined treatment group were significantly increased (P＜0.05). The FEV1% in the combined treatment group was higher than that in the blank control group (P＜0.05). FEV1/FVC was higher than the other three groups (P＜0.05). The indacaterol group, the tiotropium group and the combined treatment group BODE index score reduced(P＜0.05). The score of BODE index in the combined treatment group was lower than that of the other three groups (P＜0.05). The acute exacerbation of the patients in the combined treatment group was lighter than that in the blank control group during the treatment (P＜0.05). There was no significant difference in the incidence of adverse reactions between the four groups (P＞0.05). ConclusionWith the single application of tiotropium bromide or dutro indene severe stable COPD patients compared with two in combined therapy, can improve the pulmonary function of patients, improve the clinical treatment effect, to avoid the effect of receptor tolerance.

无